The randomized control period of the MINT trial has completed, and these newest data describe outcomes among patients who ...

On the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale, the adjusted mean difference between inebilizumab and ...

Inebilizumab, a first-in-class CD19+ B-cell–targeting agent, is safe and effective for up to 1 year in patients with ...